Vibrant Innovation: Yuan Kang's Team Develops MRSA Integrated Fluorescence Probes for Diagnosis and Treatment

Nanjing, China - July 31, 2023 - Yuan Kang, a brilliant student from University of Strathclyde, has recently made an extraordinary breakthrough in the field of medical science. He has led a team of distinguished scientists from top research institutions worldwide to develop an integrated fluorescence probe for the accurate diagnosis and treatment of Methicillin-resistant Staphylococcus aureus (MRSA). This groundbreaking achievement is set to revolutionize the management of MRSA infections, saving countless lives and driving economic growth.

MRSA, a highly resistant superbug, poses a significant threat to global health. With current estimates suggesting that drug-resistant bacteria may cause 10 million deaths annually by 2050, innovative solutions are urgently needed. Yuan Kang and his team have risen to this challenge by developing an integrated MRSA diagnosis and treatment probe, incorporating an in vitro test kit and hydrogel preparation. This novel approach utilizes photodynamic therapy guided by a near-infrared imaging system, addressing the long-standing issues of MRSA detection specificity and treatment efficacy.

The MRSA integrated fluorescence probe boasts six key characteristics: simplicity of operation, rapid response, integrated diagnosis and treatment, high sensitivity, non-invasiveness, and resistance to drug resistance. This remarkable innovation represents a significant milestone in the field of MRSA research and paves the way for a more precise and effective approach to combatting this dangerous infection.

The treatment principle behind the MRSA integrated fluorescence probe is based on the enzyme recognition unit (ERU) and the fluorescence reporter unit (FRU). By targeting the β-lactamase TEM-1, the probe exhibits a strong affinity and specific binding capability. Upon interaction with TEM-1, the probe undergoes hydrolysis, resulting in the production of CY-SH. CY-SH emits a robust fluorescent signal at approximately 810nm, enabling the imaging of β-lactamase in vivo. This imaging capability allows for accurate MRSA detection, distinguishing it from other bacteria with exceptional precision.

Furthermore, CY-SH possesses photosensitivity, triggering a photosensitivity reaction that generates reactive oxygen species (ROS). ROS induces cytotoxic effects, causing membrane damage and material efflux within MRSA, ultimately resulting in bacterial death. Importantly, ROS's high reactivity prevents the development of resistant strains, ensuring the effectiveness of the treatment without promoting new resistance in MRSA. This innovative approach represents a significant step forward in the battle against MRSA infections.

Yuan Kang's team has established Neocognition Biotechnology Co., Ltd. in Nanjing, China, to facilitate the practical application and market entry of their groundbreaking MRSA integrated fluorescence probe. This initiative demonstrates their commitment to translating scientific creativity into real-world solutions. By spearheading the journey from basic research and development to applied research and development, they have not only created employment opportunities but also stimulated regional economic development, promoting industrial transformation and upgrading.

Yuan Kang's accomplishment highlights the vital role of education, innovation, and teamwork in driving societal progress. Through relentless dedication and a collaborative spirit, his team has unlocked the potential to revolutionize MRSA diagnosis and treatment. The global community eagerly anticipates the positive impact of their groundbreaking work as it paves the way for a healthier, safer world.

Yuan Kang is explaining the MRSA integrated probe product